Abstract
Background: Inflammatory bowel disease (IBD) is increasing in Asians. We sought to better understand differences in IBD between Asians and whites in the United States (US). Methods: We used data from the Sinai-Helmsley Alliance for Research Excellence cohort to assess disease characteristics for US-born Asians, Asian immigrants, and whites. We used bivariate analyses to describe clinical characteristics by race. We used logistic regression to determine baseline odds of immunosuppression and binomial regression to estimate risk ratios for worsening disease at follow-up. Results: We included 5,223 whites, 35 US-born Asians, and 81 Asian immigrants. Crohn disease (CD) was present in 64% of whites, 40% of US-born Asians, and 51% of Asian immigrants. At baseline, 58% of whites, 62% of US-born Asians, and 67% of Asian immigrants were in remission by disease activity index score (p = 0.238). There were no significant differences in CD location and behavior or ulcerative colitis extent. Asians had significantly more perianal disease than whites (33 vs. 18%, p = 0.007). Asians were more likely to have ocular manifestations than whites (3.4 vs. 0.7%, p = 0.022). Asians were also significantly less likely to be depressed than whites (25 vs. 35%, p = 0.022). Adjusting for confounders, Asians had half the odds of being treated with biologics compared with whites (OR: 0.45, 95% CI: 0.30-0.67). Adjusting for disease behavior and remission status, there were no differences in IBD-related surgery or hospitalization, new biologic or steroid prescription, or relapse rates between Asians and whites at follow-up. Conclusion: Asians are more likely to have perianal disease and ocular extraintestinal manifestations. After controlling for confounders, Asians were less likely to be treated with biologic agents. Despite this, there were no significant differences in outcomes over time between Asians and whites. Differences in disease phenotypes in Asians may reflect differences in genetics.
References
1.
Hoeffel EM, Rastogi S, Kim MO, Shahid H: The Asian Population: 2010. 2010 Census Briefs, 2012.
2.
Ishige T, Tomomasa T, Hatori R, Tatsuki M, Igarashi Y, Sekine K, et al: Temporal trend of pediatric inflammatory bowel disease: analysis of national registry data 2004 to 2013 in Japan. J Pediatr Gastroenterol Nutr 2017;65:e80-e82.
3.
Ng WK, Wong SH, Ng SC: Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res 2016;14:111-119.
4.
Hou JK, El-Serag H, Thirumurthi S: Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review. Am J Gastroenterol 2009;104:2100-2109.
5.
Ng SC, Leung WK, Shi HY, Li MK, Leung CM, Ng CK, et al: Epidemiology of inflammatory bowel disease from 1981 to 2014: results from a territory-wide population-based registry in Hong Kong. Inflamm Bowel Dis 2016;22:1954-1960.
6.
Makharia GK, Ramakrishna BS, Abraham P, Choudhuri G, Misra SP, Ahuja V, et al: Survey of inflammatory bowel diseases in India. Indian J Gastroenterol 2012;31:299-306.
7.
Shi H, Levy AN, Trivedi HD, Chan FK, Ng SC, Ananthakrishnan AN: Ethnicity influences phenotype and outcomes in inflammatory bowel disease: a systematic review and meta-analysis of population-based studies. Clin Gastroenterol Hepatol 2017, Epub ahead of print.
8.
Malhotra R, Turner K, Sonnenberg A, Genta RM: High prevalence of inflammatory bowel disease in United States residents of Indian ancestry. Clin Gastroenterol Hepatol 2015;13:683-689.
9.
Benchimol EI, Mack DR, Guttmann A, Nguyen GC, To T, Mojaverian N, et al: Inflammatory bowel disease in immigrants to Canada and their children: a population-based cohort study. Am J Gastroenterol 2015;110:553-563.
10.
Li D, Collins B, Velayos FS, Liu L, Lewis JD, Allison JE, et al: Racial and ethnic differences in health care utilization and outcomes among ulcerative colitis patients in an integrated health-care organization. Dig Dis Sci 2014;59:287-294.
11.
Li BH, Guan X, Vittinghoff E, Gupta N: Comparison of the presentation and course of pediatric inflammatory bowel disease in South Asians with Whites: a single center study in the United States. J Pediatr 2013;163:1211-1213.
12.
Chu HP, Logarajah V, Tan N, Phua KB: Paediatric inflammatory bowel disease in a multiracial Asian country. Singapore Med J 2013;54:201-205.
13.
Ha C, Ullman TA, Siegel CA, Kornbluth A: Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol 2012;10:1002-1007; quiz e1078.
14.
Ananthakrishnan AN, Kwon J, Raffals L, Sands B, Stenson WF, McGovern D, et al: Variation in treatment of patients with inflammatory bowel diseases at major referral centers in the United States. Clin Gastroenterol Hepatol 2015;13:1197-1200.
15.
Kroenke K, Spitzer RL: The PHQ-9: a new depression diagnostic and severity measure. Psychiatr Ann 2002;32:509-515.
16.
Harvey RF, Bradsaw JM: A simple index of Crohn's-disease activity. Lancet 1980;1:514.
17.
Walmsley RS, Ayers RC, Pounder RE, Allan RN: A simple clinical colitis activity index. Gut 1998;43:29-32.
18.
Mahadev S, Young JM, Selby W, Solomon MJ: Self-reported depressive symptoms and suicidal feelings in perianal Crohn's disease. Colorectal Dis 2012;14:331-335.
19.
Herman Y, Rinawi F, Rothschild B, Nir O, Shamir R, Assa A: The characteristics and long-term outcomes of pediatric Crohn's disease patients with perianal disease. Inflamm Bowel Dis 2017;23:1659-1665.
20.
Gottgens KW, Jeuring SF, Sturkenboom R, Romberg-Camps MJ, Oostenbrug LE, Jonkers DM, et al: Time trends in the epidemiology and outcome of perianal fistulizing Crohn's disease in a population-based cohort. Eur J Gastroenterol Hepatol 2017;29:595-601.
21.
Afzali A, Cross RK: Racial and ethnic minorities with inflammatory bowel disease in the United States: a systematic review of disease characteristics and differences. Inflamm Bowel Dis 2016;22:2023-2040.
22.
Peery AF, Keku TO, Martin CF, Eluri S, Runge T, Galanko JA, et al: Distribution and characteristics of colonic diverticula in a United States screening population. Clin Gastroenterol Hepatol 2016;14:980-985.e981.
23.
Yang SK, Hong M, Baek J, Choi H, Zhao W, Jung Y, et al: A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet 2014;46:1017-1020.
24.
Kochhar R, Mehta SK, Nagi B, Bhatia V, Goenka MK, Malik AK: Extraintestinal manifestations of idiopathic ulcerative colitis. Indian J Gastroenterol 1991;10:88-89.
25.
Pokharna RK, Kabra PK, Sharma R, Kochar DK: Extraintestinal manifestations of idiopathic ulcerative colitis in northwestern India. Indian J Gastroenterol 2004;23:89-90.
26.
Basu D, Lopez I, Kulkarni A, Sellin JH: Impact of race and ethnicity on inflammatory bowel disease. Am J Gastroenterol 2005;100:2254-2261.
27.
Hauser W, Janke KH, Klump B, Hinz A: Anxiety and depression in patients with inflammatory bowel disease: comparisons with chronic liver disease patients and the general population. Inflamm Bowel Dis 2011;17:621-632.
28.
Ephgrave K: Extra-intestinal manifestations of Crohn's disease. Surg Clin North Am 2007;87:673-680.
29.
Mikocka-Walus A, Pittet V, Rossel JB, von Kanel R; Swiss IBD Cohort Study Group: Symptoms of depression and anxiety are independently associated with clinical recurrence of inflammatory bowel disease. Clin Gastroenterol Hepatol 2016;14:829-835.e821.
30.
Cross RK, Wilson KT, Binion DG: Narcotic use in patients with Crohn's disease. Am J Gastroenterol 2005;100:2225-2229.
31.
Straus WL, Eisen GM, Sandler RS, Murray SC, Sessions JT: Crohn's disease: does race matter? The Mid-Atlantic Crohn's Disease Study Group. Am J Gastroenterol 2000;95:479-483.
32.
Nguyen GC, LaVeist TA, Harris ML, Wang MH, Datta LW, Brant SR: Racial disparities in utilization of specialist care and medications in inflammatory bowel disease. Am J Gastroenterol 2010;105:2202-2208.
33.
Nguyen GC, Bayless TM, Powe NR, Laveist TA, Brant SR: Race and health insurance are predictors of hospitalized Crohn's disease patients undergoing bowel resection. Inflamm Bowel Dis 2007;13:1408-1416.
34.
Lin KK, Sewell JL: The effects of race and socioeconomic status on immunomodulator and anti-tumor necrosis factor use among ambulatory patients with inflammatory bowel disease in the United States. Am J Gastroenterol 2013;108:1824-1830.
35.
Wang J, Zuckerman IH, Miller NA, Shaya FT, Noel JM, Mullins CD: Utilizing new prescription drugs: disparities among non-Hispanic whites, non-Hispanic blacks, and Hispanic whites. Health Serv Res 2007;42:1499-1519.
36.
United States Census Bureau: Median Household Income in the Past 12 Months (in 2015 inflation-adjusted dollars). American Community Survey, 2016.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
